Department of Biostatistics
Department of Epidemiology and Preventive Health Sciences
Professor
Yasuo Ohashi, Ph.D.
Associate Professor
Yutaka Matsuyama, Ph.D.
Associate
Takuhiro Yamaguchi, Ph D., Yoichi Ito

Organization
The Department of Epidemiology and Biostatistics changed the name from "Epidemiology" in 1992 and has responsibility for providing educational courses on epidemiology and biostatistics to undergraduate students as well as graduate ones. As compared to the situation in the United States, the education of biostatistics and methodological aspects of epidemiology is poor in Japanese universities and graduate schools and the necessity for collaboration with biostatisticians in clinical research (especially clinical trials) is recently being to be claimed by clinical researchers and pharmaceutical industry. One mission of our educational courses is to provide detailed knowledge and experiences in biostatistics/epidemiology to students who are expected to take part in clinical/epidemiological research as experts and the other mission is to provide basic principles of biostatistics/epidemiology to students who will work in many health-related fields including nursing. Our main research project is the development of methodology for clinical/epidemiological research and it requires keeping touch with real clinical/epidemiological problems. For these purposes and research coordination, a non-profit organization titled 'The Japan Clinical Research Support Unit' was established by the faculty members in 2001, and the organization is providing research support in design, data management and statistical analysis in many projects inside/outside the university.
The faculty of the department is providing lectures in a series of educational courses organized by 'The Clinical Bioinformatics Research Unit' established in 2002.

Teaching Activities
1. Undergraduate courses
1) Epidemiology and Biostatistics (2 credits)
2) Applied Mathematics (2 credits)
3) Statistical Methods and Information Processing (2 credits, practice)
4) Design and Analysis of Epidemiological Research (2+1 credits, 1 practice)
5) Medical Data analysis (2 credits)
6) Biostatistics (2 credits; for the School of Pharmacy)
2. Garduate courses
1) Biostatistics (4 credits)
2) Epidemiology and Preventive Health Sciences (4 credits)
3) Introduction to Medical Statistics (2 credits; for the School of Medicine)
3. 'The Clinical Bioinformatics Research Unit' courses
1) Introduction of Biostatistics required for biomedical research
2) Methodology of Clinical Trials (2 credits)

Research Activities
1) Biostatistics and Theoretical Epidemiology
Analysis of longitudinal missing /incomplete data
Analysis of multiple events data
Analysis of QOL data
Causal analysis
Analysis of micro/macro array data
Meta analysis of epidemiological studies
2) Methodology and Information Systems for Clinical Trials
Design of clinical trials
Data management of large-scale clinical trials
3) Pharmacoepidemiology
4) Coordination of collaborative epidemiological/clinical research
Japan Longitudinal Arteriosclerosis Study
Japan Diabetes Collaborative Study
5) Consultation Works

References
  1. Ohashi Y. Lactic acid bacteria and cancer: epidemiological perspective. British Journal of Nutrition 2002; 88(Suppl 1): S121.
  2. Ohashi Y, Nakai S, Tsukamoto T, Masumori N, Akaza H, Miyanaga N, Kitamura T, Kawabe K, Kotake T, Kuroda M, Naito S, Koga H, Saito Y, Nomata K, Kitagawa M, Aso Y. Habitual intake of lactic acid bacteria and risk reduction of bladder cancer. Urologia Internationalis 2002; 68: 273-280.
  3. The EPOCH Study Group. Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure -the effects of pimobendan on chronic heart failure study (EPOCH Study)-. Circulation Journal 2002; 66(2): 149-157.
  4. Kato T. Ohashi Y, Nakazato H, Koike A, Saji S, Suzuki H, Takagi H, Nimura Y, Hasumi A, Baba S, Manabe T, Maruta M, Miura K, Yamaguchi A. Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trial. Langenbeck's Archives of Surgery 2002; 386: 575-581.
  5. Koshikawa S, Akizawa T, Kurokawa K, Marumo F, Sasaki O, Arakawa M, Morii H, Seino Y, Ogata E, Ohashi Y, Akiba T, Tsukamoto Y, Suzuki M. Clinical effect of intravenous calcitriol administration on secondary hyperparathyroidism. A double-blind study among 4 doses. Nephron 2002; 90: 413-423.
  6. Matsumoto T, Ohashi Y, Morita S, Kobayashi K, Shibuya M, Yamaji Y, Eguchi K, Fukuoka M, Nagao K, Nishiwaki Y, Niitani H. for the CPT-11 Lung Cancer Study Group West and East. The quality of life questionnaire for cancer patients treated with anticancer drugs (QOL-ACD): validity and reliability in Japanese patients with advanced non-small-cell lung cancer. Quality of Life Research 2002; 11: 483-493.
  7. Sakamoto J, Teramukai S, Nakazato H, Sato Y, Uchino J, Taguchi T, Ryoma Y, Ohashi Y. Efficacy of adjuvant immunochemotherapy with OK-432 for patients with curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials. Journal of Immunotherapy 2002; 25(5): 405-412.
  8. Samizo K, Kawabe E, Hinotsu S, Sato T, Kageyama S, Hamada C, Ohashi Y, Kubota K. Comparison of losartan with ACE inhibitors and dihydropyridine calcium channel antagonists. Drug Safety 2002; 25(11): 811-821.
  9. Sarkar S, Watts S, Ohashi Y, Carrol RJ, Uesaka H, Mason TM, Rivera C. Bridging data between two ethnic populations. A new application of matched case-control methodology. Drug Information Journal 2002; 36: 349-356.
  10. Sone H, Katagiri A, Ishibashi S, Abe R, Saito Y, Murase T, Yamashita H, Yajima Y, Ito H, Ohashi Y, AkanumaY, Yamada N, JDC Study Group. Effects of lifestyle modifications on patients with type 2 diabetes: the Japan diabetes complications study （JDCS） study design, baseline analysis and three year-interim report. Hormone and Metabolic Research 2002; 34: 509-515.
  11. Tominaga T, Toi M, Abe O, Ohashi Y, Uchino J, Hayasaka H, Abe R, Izuo M, Enomoto K, Watanabe H, Yoshida M, Taguchi T, Koyama H, Senoo T, Toge T, Monden Y, Hattori T, Nomura Y, Sugimachi K, Hirata K, Nakazato H, Miura S, Morimoto T, Asaishi K, Kimijima I, Ota J, Sonoo H, Yamaguchi S, The 5'-BC Study Group (5'-DFUR Adjuvant Chemotherapy for Breast Cancer Study Group). The effect of adjuvant 5'-deoxy-5'-fluorouridine in early stage breast cancer patients: results from a multicenter randomized controlled trial. International Journal of Oncology 2002; 20: 517-525.
  12. Tominaga T, Toi M, Ohashi Y, Abe O, 5'-BC Study Group. Prognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patients. Clinical Breast Cancer 2002; 3(1): 55-64.Matsuyama Y. Correcting for non-compliance of repeated binary outcomes in randomized clinical trials: Randomized analysis approach. Statistics in Medicine 2002; 21: 657-687.
  13. Miyagawa Y, Imamura H, Soeda J, Matsunaga K, Mochida S, Fujiwara K, Matsuyama Y, Kawasaki S. Fate of hepatocyte and sinusoidal lining cell function and kinetics after extended cold preservation and transplantation of the rat liver. Liver Transplantation 2002; 8(4): 370-381.
  14. Imamura H, Takayama T, Sugawara Y, Kokudo N, Aoki T, Kaneko J, Matsuyama Y, Sano K, Maema A, Makuuchi M. Pringle's maneuver in living donors. Lancet 2002; 360: 2049-2050.
  15. Homma Y, Yamaguchi T, Kondo Y, Horie S, Takahashi S, Kitamura T. Significance of nocturia in the International Prostate Symptom Score for benign prostatic hyperplasia. Journal of Urology 2002; 167(1): 172-176.
  16. Kodama Y, Kodama H, Kuranari M, Tsutsumi K, Ono S, Yamaguchi T, Fujimura A. Protein binding of valproic acid in Japanese pediatric and adult patients with epilepsy. American Journal of Health-system Pharmacy 2002; 59: 835-840.
  17. Yamaguchi T, Matsuyama Y, Ohashi Y. Proportional hazards models with random effects to examine center effects in multicenter cancer clinical trials. Statistical Methods in Medical Research 2002; 11(3): 221-236.
  18. Yamaguchi T, Hashimoto S, Oka S, Yoshizaki K, Kimura S, Fukutake K, Shirasaka T. Physical condition and activity of daily living among HIV patients infected through blood products in Japan. Journal of Epidemiology 2002; 12(5): 383-393.
  19. Wang L, Yamaguchi T, Yoshimine T, Katagiri A, Shirogane K, Ohashi Y. A case-control study of risk factors for development of type 2 diabetes: emphasis on physical activity. Journal of Epidemiology 2002; 12(6): 424-430.
  20. Tanaka N, Asada T, Kinoshita T, Fumio Y, Uno M. Alcohol consumption and risk of dementia. (letter) Lancet 2002; 360: 491
  21. Asukai N, Kato H, Kawamura N, Kim Y, Yamamoto K, Kishimoto J, Miyake Y, Nishizono-Maher A. Reliability and validity of the Japanese-language version of the impact of event scale-revised (IES-R-J): four studies of different traumatic events. The Journal of Nervous and Mental Health 2002; 190(3): 175-182.
  22. Negoro S, Masuda N, Takada Y, Sugiura T, Kudoh T, Katakami N, Ariyoshi Y, Ohashi Y, Niitani H, Fukuoka M, CPT-11 Lung Cancer Study Group West. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. British Journal of Cancer 2003; 88(3): 335-341.
  23. Sone H, Ito H, Akanuma Y, Yamada N, Japan Diabetes Complication Study Group. Obesity and type 2 diabetes in Japanese patients. Lancet 2003; 361(9351): 85.
  24. Tominaga T, Koyama H, Toge T, Miura T, Sugimachi K, Yamaguchi S, Hirata K, Monden T, Nomura Y, Masakazu T, Kimijima I, Noguchi S, Sonoo H, Asaishi K, Ikeda T, Morimoto T, Ota J, Ohashi Y, Abe O. Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery. Journal of Clinical Oncology 2003; 21(6): 991-998.
  25. Akaza H, Homma Y, Okada K, Yokoyama M, Usami M, Hirao Y, Tsushima T, Ohashi Y, Aso Y, Prostate Cancer Study Group. A prospective and randomized study of primary hormonal therapy for patients with localized or locally advanced prostate cancer unsuitable for radical prostatectomy: results of the 5-year follow-up. BJU International 2003; 91(1): 33-36.
  26. Tobinai K, Uike N, Saburi Y, Chou T, Etoh T, Masuda M, Kawano F, Matsuoka M, Taguchi H, Makino T, Asano Y, Tamura K, Ohashi Y, Cladribine/ATL Study Group, Japan. Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma. International Journal of Hematology 2003; 77(5): 512-517.
  27. Sakamoto J, Teramukai S, Ohashi Y. Design and methodology of meta-analysis to show the efficacy of OK-432. Annals of Cancer Research and Therapy 2003; 10: 89-92.
  28. Morita S, Kobayashi K, Eguchi K, Matsumoto T, Shibuya M, Yamaji Y, Sakamoto J, Ohashi Y. Influence of clinical parameters on quality of life during chemotherapy in patients with advanced non-small cell lung cancer: application of a general linear model. Japanese Journal of Clinical Oncology 2003; 33(9): 470-476.
  29. Morita S, Ohashi Y, Kobayashi K, Matsumoto T, Eguchi K, Shibuya M, Yamaji Y, Fukuoka M, Nagao K, Niitani H, West and East CPT-11 Lung Cancer Study Groups. Individually different "weights" of quality of life assessment in patients with advanced nonsmall-cell lung cancer. Journal of Clinical Epidemiology 2003; 56(8): 744-751.
  30. Morii H, Ohashi Y, Taketani Y, Fukunaga M, Nakamura T, Itabashi A, Sarkar S, Harper K. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial. Osteoporosis International 2003; 14(10): 793-800.
  31. Matsuyama Y. Sensitivity analysis for the estimation of rates of change with non-ignorable drop-out: An application to a randomized clinical trial of the vitamin D3. Statistics in Medicine. 2003; 22: 811-827.
  32. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, Minagawa M, Takayama T, Kawasaki S, Makuuchi M. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. Journal of Hepatology 2003; 38: 200-207.
  33. Sato T, Matsuyama Y. Marginal structural models as a tool for standardization. Epidemiology 2003; 14(6): 680-686.
  34. Ogihara N, Ebihara S, Kawamura W, Okamoto M, Sakai T, Takiguchi K, Morita T, Uchida R, Matsuyama Y, Hayashi Y, Arakawa Y, Kikuchi, M. Characterization of the portal signal in a non-steady hyperglycemic state in conscious dogs. American Journal of Physiology - Endoclinology and Metabolism 2003; 284: 148-155.
  35. Matsuyama Y. Editorial comments: Comparison of outcomes of three different surgical techniques performed for stress urinary incontinence. International Journal of Urology. 2003; 10: 131.
  36. Matsui Y, Saiura A, Sugawara Y, Sata M, Naruse K, Yagita H, Kohro T, Mataki C, Izumi A, Yamaguchi T, Minami T, Sakihama T, Ihara S, Aburatani H, Hamakubo T, Kodama T, Makuuchi M. Identification of gene expression profile in tolerizing murine cardiac allograft by costimulatory blockade. Physiologic Genomics 2003; 15(3): 199-208.
  37. Wang Y, Kato N, Hoshida Y, Yoshida H, Taniguchi H, Goto T, Moriyama M, Otsuka M, Shiina S, Shiratori Y, Ito Y, Omata M.Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology 2003; 37(1): 65-71.
  38. Kawado M, Hinotsu S, Matsuyama Y, Yamaguchi T, Hashimoto S, Ohashi Y. A comparison of error detection rates between the reading aloud method and the double data entry method. Controlled Clinical Trials 2003; 24: 560-569.
  39. Tanaka N, Kinoshita T, Asada T, Ohashi Y. Log-linear models for assessing gene-age interaction and their application to case-control studies of the apolipoprotein E (apoE) gene in Alzheimer's disease. Journal of Human Genetics 2003;48(10):520-524.
  40. Sakamoto J, Morita S, Yumiba T, Narahara H, Kinoshita K, Nakane Y, Imamoto H, Shiozaki H, Ascitic Gastric Cancer Study Group of the Japan South West Oncology Group. A phase II clinical trial to evaluate the effect of paclitaxel in patients with ascites caused by advanced or recurrent gastric carcinoma: a new concept of clinical benefit response for non-measurable type of gastric cancer. Japanese Journal of Clinical Oncology 2003; 33(5): 238-240.
Annual Report of the Graduate School of Medicine and The Faculty of Medicine The University of Tokyo Reports for the Period April 2002 - March 2004